TGFB1 and neoplasm: We examined whether combining GVAX with a monoclonal pan-TGF-β neutralizing antibody, which blocks all 3 of the TGF-β subtypes (αTGF-β), TGF-β 1,2, & 3, could improve the anti-tumor activity of GVAX in two hepatic metastatic PDA models.